Newsletter - CADRE Diabetes

	12/15/2012 Volume 10:2 - Autumn 2012 - Controversies in Care More Evidence, Less Conviction: From the Editor-in-Chief - Desmond A. Schatz, MD Is There a Role for Thiazolidinediones in the Treatment of Type 2 Diabetes? No - Irl Hirsch, MD Yes - Rucha J. Mehta, MD and Ralph A. DeFronzo, MD Is There a Relationship Between Insulin Use and Increased Cancer Risk? - Edward Giovannucci, MD Insulin Glargine Safety: Recent Findings Suggest No Increase in Cancer Risk - Caitlin Rothermel, MA

	4/1/2006 AADE Proceedings Newsletter Intensive Diabetes Control: Reaping the Benefits Promised by Clinical Trials Patient Education: Addressing Multiple Risk Factors Through Medical Nutrition Therapy Overcoming Barriers to Intensive Insulin Administration

	1/1/2006 Roberta McDuffie, APRN, BC, MSN, CDE, CNS DO YOU THINK PATIENTS WITH PREDIABETES SHOULD BE STARTED ON EITHER ORAL AGENTS OR INSULIN? WHAT ABOUT STATINS AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS?

	1/1/2006 Melinda Maryniuk, MEd, RD, FADA, CDE WHAT ABOUT TAKING VITAMIN E OR OTHER ANTIOXIDANT SUPPLEMENTS TO REDUCE CARDIOVASCULAR DISEASE RISK?

	1/1/2006 William T. Cefalu, MD DO YOU SEE A ROLE FOR INSULIN INFUSION THERAPY DURING ACUTE MYOCARDIAL INFARCTION?

CADRE Newsletters

Other Newsletters

Archived Newsletters

©2011 CADRE - Council for the Advancement of Diabetes Research and Education.
All information, materials, functions, and other content ("Content") contained on the CADRE site is our copyrighted property or the copyrighted property of our licensors or licensees. Except as we specifically agree in writing, no Content from the CADRE site may be used, reproduced, transmitted, distributed or otherwise exploited in any way other than as part of the CADRE site, except that where a CADRE site is configured to enable the download of particular Content, you may download one copy of such Content to a single computer for your personal, noncommercial home use only, provided that you (a) keep intact all copyright and other proprietary notices, (b) make no modifications to the Content, and (c) do not use the Content in a manner that suggests an association with any of our products, services or brands.